Pyxis Oncology, INC 8-K filings
NASDAQ
Pyxis Oncology announced its first quarter 2024 financial results, provided updates on its clinical programs, and appointed a new Chief Business Officer.
NASDAQ
Pyxis Oncology has released updated unaudited pro forma financial information to reflect the acquisition of Apexigen, showing combined results as if the merger occurred at the beginning of 2023.
NASDAQ
Pyxis Oncology has sold its royalty rights for Beovu and another asset to Novartis for $8 million, providing non-dilutive funding for its lead ADC asset.
NASDAQ
Pyxis Oncology announced its full year 2023 financial results and provided a corporate update, highlighting progress in its clinical trials and a recent $50 million private placement.
NASDAQ
Pyxis Oncology has appointed Santhosh Palani, Ph.D., CFA, to its Board of Directors, effective March 12, 2024.
NASDAQ
Pyxis Oncology has successfully raised $50 million through a private placement to fund the development of its lead drug candidate and for general corporate purposes.